The size of the stake to be sold was not clear, the same official said.
Another source close to the deal said Actera was buying a 10 percent stake in the drugmaker in a deal valuing the company at over $900 million.
Bilim Ilac is one of the top 2 players in the domestic market, according to its website.
In April, sources familiar with the deal said European buyout firms Cinven, CVC and Advent International were among potential buyers of a stake in Bilim Ilac.
Bilim Ilac had a 5.1 percent market share in 2010, according to the company’s website. The Turkish drug market had revenue of 14.8 billion lira ($9.74 billion) in 2010, according to Bilim Ilac.
Turkey is attracting larger generic manufacturers and major drugmakers with one of the highest economic growth rates in Europe and robust growth in the pharmaceutical market.
